#1 - CRISPR Therapeutics (NASDAQ:CRSP)
When you hear about gene editing, you’ll frequently hear about CRISPR-Cas9 technology. The visual picture of this technology is using a pair of scissors to splice out an offending gene.
CRISPR-Cas9 is the proprietary gene editing technology developed by CRISPR Therapeutics AG (NASDAQ: CRSP). And as one of the leading names in the sector, it should be one for investors to consider.
The company’s lead candidate, CASGEVY, received approval for the treatment of sickle cell disease from the U.S. Food & Drug Administration (FDA) in December 2023. In January 2024, the label for CASGEVY was expanded to include beta-thalassemia.
CRISPR is partnering with Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) to market CASGEVY and the company will only receive 40% of the revenue Vertex generates from marketing the drug. The company also faces issues dealing with accessibility (there are only 25 treatment centers worldwide). And health insurers have yet to weigh in on how much of the drug’s $2.2 million price tag for one treatment they will cover.
Those are to be expected for a company that is first to market with a revolutionary treatment. But now that the company has opened the door, it may be time for investors to get involved.
About CRISPR Therapeutics
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Read More - Current Price
- $47.25
- Consensus Rating
- Hold
- Ratings Breakdown
- 9 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings.
- Consensus Price Target
- $74.94 (58.6% Upside)
